바이오솔루션
086820KOSDAQ· 의료용 물질 및 의약품 제조업6,470원0 (0.00%)마감후장 마감 후
52주 위치
5,24013,45015%신고가 대비 -51.90%
- 시가총액
- 1,677억
- PER
- 157.80
- PBR
- 4.06
- EPS(TTM)
- 41원
- BPS
- 1,594원
- 자사주비율
- 0.46%
- 결산월
- 12월
알림 만들기관심종목·메모·논지·저널은 로그인하면 사용 가능
| 항목 | 2021(별도) | 2022(별도) | 2023(별도) | 2024(별도) | 2025(별도) |
|---|---|---|---|---|---|
| ROE | -3.74% | -18.22% | -2.91% | -32.48% | 0.86% |
| ROA | -1.78% | -8.69% | -1.36% | -14.92% | 0.40% |
| 영업이익률 | -13.32% | -52.36% | -40.38% | -39.33% | -28.39% |
| 순이익률 | -14.28% | -80.06% | -10.02% | -92.55% | 1.80% |
| 매출총이익률 | 64.46% | 58.68% | 65.16% | 63.32% | 63.12% |
| 부채비율 | 109.73% | 109.55% | 119.03% | 115.83% | 113.95% |
| 유동비율 | 178.17% | 172.64% | 94.14% | 62.85% | 52.18% |
| 매출 성장률(YoY) | — | -14.41% | 23.36% | 3.42% | 18.01% |
| FCF | -3.05억 | -73.65억 | 11.46억 | -26.66억 | -14.48억 |
| FCF 마진 | -2.58% | -72.91% | 9.20% | -20.69% | -9.52% |
| CAPEX/매출 | 3.29% | 35.16% | 8.13% | 2.95% | 1.22% |
| 항목 | 2021 3Q(별도) | 2021 4Q(별도) | 2022 1Q(별도) | 2022 2Q(별도) | 2022 3Q(별도) | 2022 4Q(별도) | 2023 1Q(별도) | 2023 2Q(별도) | 2023 3Q(별도) | 2023 4Q(별도) | 2024 1Q(별도) | 2024 2Q(별도) | 2024 3Q(별도) | 2024 4Q(별도) | 2025 1Q(별도) | 2025 2Q(별도) | 2025 3Q(별도) | 2025 4Q(별도) | 2026 1Q(별도) | 2026 2Q(별도) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.13% | -7.51% | -3.39% | -8.76% | -9.30% | 3.33% | -2.45% | -5.77% | -3.67% | 8.69% | -8.54% | -1.71% | -6.90% | -14.06% | -7.14% | -2.79% | -5.93% | 17.39% | -5.74% | -2.12% |
| ROA | 2.09% | -3.58% | -1.56% | -4.10% | -4.45% | 1.59% | -1.13% | -2.64% | -1.62% | 4.06% | -3.84% | -0.77% | -3.21% | -6.46% | -3.13% | -1.26% | -2.76% | 8.09% | -3.09% | -1.14% |
| 영업이익률 | 8.43% | -55.71% | -56.02% | -65.30% | -33.81% | -60.29% | -37.29% | -38.98% | -46.22% | -38.67% | -101.73% | -21.69% | -36.61% | -13.28% | -43.87% | -44.03% | -24.37% | -10.44% | -34.00% | -9.44% |
| 순이익률 | 48.58% | -155.83% | -70.15% | -176.44% | -136.27% | 54.90% | -39.40% | -79.23% | -46.79% | 106.48% | -135.14% | -20.86% | -75.58% | -144.04% | -77.10% | -30.33% | -41.14% | 124.27% | -54.18% | -15.65% |
| 매출총이익률 | 74.15% | 52.39% | 56.15% | 56.35% | 63.07% | 57.50% | 65.67% | 61.86% | 60.35% | 72.03% | 59.28% | 63.07% | 61.48% | 68.20% | 64.94% | 58.93% | 62.37% | 65.55% | 65.21% | 69.32% |
| 부채비율 | 97.49% | 109.73% | 116.99% | 113.48% | 122.54% | 109.55% | 115.04% | 123.48% | 130.51% | 119.03% | 130.62% | 120.79% | 97.61% | 115.83% | 124.46% | 124.67% | 137.76% | 113.95% | 59.05% | 61.26% |
| 유동비율 | 189.88% | 178.17% | 172.48% | 173.85% | 166.69% | 172.64% | 172.69% | 162.77% | 160.02% | 94.14% | 89.09% | 78.96% | 64.67% | 62.85% | 57.38% | 54.75% | 54.53% | 52.18% | 74.34% | 76.70% |
| 매출 성장률(YoY) | — | — | — | — | -24.98% | 24.30% | 27.00% | 40.53% | 2.81% | 30.20% | -4.38% | 7.20% | 7.79% | 2.15% | 21.80% | -4.86% | 31.43% | 23.45% | 19.87% | 50.13% |
| 영업이익 성장률(YoY) | — | — | — | — | -400.80% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| 순이익 성장률(YoY) | — | — | — | — | -310.43% | — | — | — | — | 152.54% | — | — | — | -238.18% | — | — | — | — | — | — |
| FCF | 5.64억 | -14.65억 | -6.7억 | -11.55억 | -23.25억 | -32.16억 | 9.06억 | -8.1억 | -7.25억 | 17.75억 | -9.67억 | -10.81억 | -8.03억 | 1.85억 | -7.13억 | -10.09억 | -475만 | 2.79억 | -2.43억 | 2.73억 |
| FCF 마진 | 13.66% | -67.58% | -31.55% | -52.82% | -75.04% | -119.32% | 33.60% | -26.36% | -22.76% | 50.58% | -37.53% | -32.83% | -23.40% | 5.17% | -22.71% | -32.21% | -0.11% | 6.29% | -6.45% | 5.80% |
| CAPEX/매출 | 2.41% | 1.21% | 26.19% | 35.85% | 40.03% | 36.06% | 4.57% | 13.51% | 9.01% | 5.38% | 1.70% | 7.35% | 0.70% | 1.95% | 0.06% | 4.65% | 0.49% | 0.34% | 1.53% | 1.26% |
출처 DART 재무제표 원값으로 자체 계산· 갱신 2026-09-21 00:18· 별도 · 산식은 항목 툴팁